Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 69

Sort by

Sort Order Select

Journal Articles

CNS Relapse in High-Grade B-cell Lymphoma with MYC and BCL2 Rearrangements and Dark-Zone Signature-Expressing DLBCL

Waleed Alduaij, Aixiang Jiang, Diego Villa, Brett J Collinge, Susana Ben-Neriah, Merrill Boyle, Barbara Meissner, Laura K Hilton, Pedro Farinha, Graham W. Slack, Jeffrey W Craig, Alina S. Gerrie, Ciara L Freeman, Andrew J Mungall, Christian Steidl, Laurie H. Sehn, David W. Scott, Kerry J. Savage

Blood blood.2024025725.

https://doi.org/10.1182/blood.2024025725

Published: 2024

Includes: Supplemental data

Journal Articles

Unbalanced MYC break-apart FISH patterns indicate the presence of a MYC rearrangement in HGBCL-DH- BCL2

Brett Collinge, Susana Ben-Neriah, Laura K. Hilton, Waleed Alduaij, Tracy Tucker, Graham W. Slack, Pedro Farinha, Jeffrey W. Craig, Merrill Boyle, Barbara Meissner, Diego Villa, Alina S. Gerrie, Laurie H. Sehn, Kerry J. Savage, Ryan D. Morin, Andrew J. Mungall, Christian Steidl, David W. Scott

Blood (2024) 144 (15): 1611–1616.

https://doi.org/10.1182/blood.2024025603

Published: 2024

Includes: Supplemental data

Journal Articles

Motive and opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements (an LLMPP study)

Blood (2024) 144 (5): 525–540.

https://doi.org/10.1182/blood.2024024251

Published: 2024

Includes: Supplemental data

Journal Articles

Genetic subdivisions of follicular lymphoma defined by distinct coding and noncoding mutation patterns

Blood (2023) 142 (6): 561–573.

https://doi.org/10.1182/blood.2022018719

Published: 2023

Includes: Supplemental data

Journal Articles

Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population

Blood (2023) 141 (20): 2493–2507.

https://doi.org/10.1182/blood.2022018248

Published: 2023

Includes: Supplemental data

Journal Articles

Relapse Timing Is Associated with Distinct Evolutionary Dynamics and Response to Salvage Therapy in DLBCL

Blood (2022) 140 (Supplement 1): 1310–1312.

https://doi.org/10.1182/blood-2022-160187

Published: 2022

Journal Articles

Long-Term Outcomes of High-Risk Stage 1/2 Classic Hodgkin Lymphoma Managed with an Advanced Stage Treatment Approach

Jowon Laura Kim, Diego Villa, R. Petter Tonseth, Alina S. Gerrie, Don Wilson, Francois Benard, Christopher P. Venner, Brian Skinnider, Pedro Farinha, Graham W. Slack, Randy D. Gascoyne, David W. Scott, Joseph M. Connors, Laurie H. Sehn, Kerry J. Savage

Blood (2022) 140 (Supplement 1): 9437–9438.

https://doi.org/10.1182/blood-2022-162199

Published: 2022

Journal Articles

Do Unbalanced MYC Break-Apart FISH Patterns Indicate the Presence of a MYC Rearrangement?

Brett Collinge, Susana Ben-Neriah, Laura K Hilton, Waleed Alduaij, Tracy Tucker, Graham W Slack, Pedro Farinha, Jeffrey W. Craig, Merrill Boyle, Barbara Meissner, Kelly Mekwunye, Diego Villa, Alina S. Gerrie, Laurie H. Sehn, Kerry J. Savage, Ryan D. Morin, Andrew J. Mungall, Christian Steidl, David W. Scott

Blood (2022) 140 (Supplement 1): 9244–9246.

https://doi.org/10.1182/blood-2022-170065

Published: 2022

Journal Articles

Risk of Central Nervous System Involvement in High-Grade B-Cell Lymphoma with MYC and BCL2 Rearrangements: Analysis of a Population-Based Cohort with Routine Fluorescence in Situ Hybridization Testing in British Columbia

Waleed Alduaij, Aixiang Jiang, Diego Villa, Brett Collinge, Susana Ben-Neriah, Merrill Boyle, Barbara Meissner, Laura K Hilton, Pedro Farinha, Graham W Slack, Jeffrey W. Craig, Alina S. Gerrie, Ciara L. Freeman, Andrew J. Mungall, Christian Steidl, Laurie H. Sehn, David W. Scott, Kerry J. Savage

Blood (2022) 140 (Supplement 1): 1332–1333.

https://doi.org/10.1182/blood-2022-159356

Published: 2022

Journal Articles

Long-Term Outcomes of Patients Aged 65 Years or Older with Peripheral T-Cell Lymphoma, Not Otherwise Specified (PTCL-NOS) and T-Follicular Helper T-Cell Lymphoma (TFHTCL) Treated with Curative Intent CHOP(like) Chemotherapy

Henry S. Ngu, Diego Villa, Alina S. Gerrie, Christopher P. Venner, Andrew Lytle, Brian Skinnider, Jeffrey W. Craig, Graham W. Slack, David W. Scott, Laurie H. Sehn, Kerry J. Savage

Blood (2022) 140 (Supplement 1): 3713–3715.

https://doi.org/10.1182/blood-2022-168586

Published: 2022

Journal Articles

TRAF3 Loss-of-Function Reveals the Non-Canonical NF-Κb Pathway As a Therapeutic Target in Diffuse Large B-Cell Lymphoma

Michael Y. Li, Lauren C. Chong, Bruce W Woolcock, Adèle Telenius, Susana Ben-Neriah, Graham W Slack, Vivian Lam, Aixiang Jiang, Elena Viganò, Tomohiro Aoki, Shannon Healy, Gerald Krystal, Leandro Venturutti, David W. Scott, Christian Steidl

Blood (2022) 140 (Supplement 1): 2042–2043.

https://doi.org/10.1182/blood-2022-159679

Published: 2022

Journal Articles

Genetic Determinants of Isolated and Systemic Testicular Diffuse Large B-Cell Lymphoma Highlight a Disease Spectrum

Blood (2022) 140 (Supplement 1): 6374–6375.

https://doi.org/10.1182/blood-2022-165546

Published: 2022

Journal Articles

B-lymphoblastic lymphoma presenting as a primary breast mass with periductal invasion

Kevin E. Shopsowitz, Graham W. Slack

Blood (2021) 138 (24): 2593.

https://doi.org/10.1182/blood.2021013172

Published: 2021

Journal Articles

Immune Profiling of Diagnostic DLBCL Biopsies Dramatically Improves upon Cell-of-Origin Risk Stratification

Michael Nissen, Xuehai Wang, Clementine Sarkozy, Aixiang Jiang, Daisuke Ennishi, Tomohiro Aoki, Stacy Hung, Elizabeth Chavez, Jeffrey W Craig, Pedro Farinha, Graham W. Slack, David W. Scott, Christian Steidl, Andrew P. Weng

Blood (2021) 138 (Supplement 1): 719.

https://doi.org/10.1182/blood-2021-154082

Published: 2021

Journal Articles

Constrained FL: A Genetically Distinct Subgroup of Follicular Lymphoma with Low Rates of Somatic Hypermutation and a Reduced Propensity for Histologic Transformation

Blood (2021) 138 (Supplement 1): 807.

https://doi.org/10.1182/blood-2021-153445

Published: 2021

Journal Articles

Diffuse Large B-Cell Lymphoma (DLBCL) Patients with Late Relapses Who Are Transplant-Eligible Have Excellent Outcomes and May Represent Unique Biology

Henry S. Ngu, Laura K Hilton, Judith Anula Rodrigo, Diego Villa, Alina S. Gerrie, Kevin Song, Pedro Farinha, Graham W. Slack, Kerry J. Savage, David W. Scott, Laurie H. Sehn

Blood (2021) 138 (Supplement 1): 2499.

https://doi.org/10.1182/blood-2021-149049

Published: 2021

Journal Articles

The Genomic Landscape of Plasmablastic Lymphoma (PBL) - an L.L.M.P.P. Project

Blood (2021) 138 (Supplement 1): 1326.

https://doi.org/10.1182/blood-2021-153441

Published: 2021

Journal Articles

Outcome of Relapsed and Refractory Peripheral T-Cell Lymphoma (PTCL) with Intention for Curative Therapy Incorporating High Dose Chemotherapy and Hematopoietic Stem Cell Transplant (HDC/SCT)

Henry S. Ngu, Stephen Parkin, David W. Scott, Diego Villa, Alina S. Gerrie, Cynthia L. Toze, Maryse Power, Graham W Slack, Joseph M. Connors, Kevin Song, Laurie H. Sehn, Kerry J. Savage

Blood (2021) 138 (Supplement 1): 624.

https://doi.org/10.1182/blood-2021-146352

Published: 2021

Journal Articles

Frontline Therapy with Bendamustine-Rituximab (BR) in Patients with Treatment-Naïve Waldenstrom's Macroglobulinemia Confers Similar Long-Term Outcomes to R-CVP in a Real-World Setting: A Population-Based Analysis

Jowon Laura Kim, Alina S. Gerrie, Kerry J. Savage, Diego Villa, David W. Scott, Jeffrey W Craig, Pedro Farinha, Brian Skinnider, Graham W. Slack, Joseph M. Connors, Laurie H. Sehn, Ciara L. Freeman

Blood (2021) 138 (Supplement 1): 1353.

https://doi.org/10.1182/blood-2021-146738

Published: 2021

Journal Articles

Population-Wide Introduction of Dose-Adjusted EPOCH-R Is Associated with Improved Outcome of High Grade B-Cell Lymphoma with MYC and BCL2 Rearrangements with Diffuse Large B-Cell Lymphoma Morphology

Blood (2021) 138 (Supplement 1): 1458.

https://doi.org/10.1182/blood-2021-145954

Published: 2021

NARROW

CNS Relapse in High-Grade B-cell Lymphoma with MYC and BCL2 Rearrangements and Dark-Zone Signature-Expressing DLBCL

Unbalanced MYC break-apart FISH patterns indicate the presence of a MYC rearrangement in HGBCL-DH- BCL2

Motive and opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements (an LLMPP study)

Genetic subdivisions of follicular lymphoma defined by distinct coding and noncoding mutation patterns

Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population

Relapse Timing Is Associated with Distinct Evolutionary Dynamics and Response to Salvage Therapy in DLBCL

Long-Term Outcomes of High-Risk Stage 1/2 Classic Hodgkin Lymphoma Managed with an Advanced Stage Treatment Approach

Do Unbalanced MYC Break-Apart FISH Patterns Indicate the Presence of a MYC Rearrangement?

Risk of Central Nervous System Involvement in High-Grade B-Cell Lymphoma with MYC and BCL2 Rearrangements: Analysis of a Population-Based Cohort with Routine Fluorescence in Situ Hybridization Testing in British Columbia

Long-Term Outcomes of Patients Aged 65 Years or Older with Peripheral T-Cell Lymphoma, Not Otherwise Specified (PTCL-NOS) and T-Follicular Helper T-Cell Lymphoma (TFHTCL) Treated with Curative Intent CHOP(like) Chemotherapy

TRAF3 Loss-of-Function Reveals the Non-Canonical NF-Κb Pathway As a Therapeutic Target in Diffuse Large B-Cell Lymphoma

Genetic Determinants of Isolated and Systemic Testicular Diffuse Large B-Cell Lymphoma Highlight a Disease Spectrum

B-lymphoblastic lymphoma presenting as a primary breast mass with periductal invasion

Immune Profiling of Diagnostic DLBCL Biopsies Dramatically Improves upon Cell-of-Origin Risk Stratification

Constrained FL: A Genetically Distinct Subgroup of Follicular Lymphoma with Low Rates of Somatic Hypermutation and a Reduced Propensity for Histologic Transformation

Diffuse Large B-Cell Lymphoma (DLBCL) Patients with Late Relapses Who Are Transplant-Eligible Have Excellent Outcomes and May Represent Unique Biology

The Genomic Landscape of Plasmablastic Lymphoma (PBL) - an L.L.M.P.P. Project

Outcome of Relapsed and Refractory Peripheral T-Cell Lymphoma (PTCL) with Intention for Curative Therapy Incorporating High Dose Chemotherapy and Hematopoietic Stem Cell Transplant (HDC/SCT)

Frontline Therapy with Bendamustine-Rituximab (BR) in Patients with Treatment-Naïve Waldenstrom's Macroglobulinemia Confers Similar Long-Term Outcomes to R-CVP in a Real-World Setting: A Population-Based Analysis

Population-Wide Introduction of Dose-Adjusted EPOCH-R Is Associated with Improved Outcome of High Grade B-Cell Lymphoma with MYC and BCL2 Rearrangements with Diffuse Large B-Cell Lymphoma Morphology

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only